Evidence map›Paper›PMID 33218057›Full record

ArticleInternational journal of molecular sciences2020

Matrix Metalloproteinases MMP-2 and MMP-9, Their Inhibitors TIMP-1 and TIMP-2, Vascular Endothelial Growth Factor and sVEGFR-2 as Predictive Markers of Ischemic Retinopathy in Patients with Systemic Sclerosis-Case Series Report.

Arleta Waszczykowska, Michał Podgórski, Michał Waszczykowski, Zofia Gerlicz-Kowalczuk, Piotr Jurowski

Open access · goldAbstract readCase Reports
In one paragraph

Article in International journal of molecular sciences, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.

0numbers the graph read from it
0cells of the map it votes in
16citing papers in PubMed
1.9field-weighted citation impact, top 14% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

16 citing papers in PubMed, 29 citations in OpenAlex.

  1. Review
  2. Review
  3. Article
  4. Review
  5. Article
  6. Review
  7. Review
  8. Review
  9. Article
  10. Bergenin alleviates Diabetic Retinopathy in STZ-induced rats.Applied biochemistry and biotechnology · 2023
    Article
  11. Review
  12. Review
  13. Review
  14. Article
  15. Article
  16. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 2 institutions in 1 country.

Arleta WaszczykowskaDepartment of Ophthalmology and Vision Rehabilitation, Medical University of Lodz, Zeromskiego 113, 90-549 Lodz, Poland.ORCID 0000-0002-4950-6390
Michał PodgórskiDepartment of Diagnostic Imaging, Polish Mother's Memorial Hospital Research Institute, Rzgowska 281/289, 93-338 Lodz, Poland.ORCID 0000-0003-4513-0602
Michał WaszczykowskiDepartment of Arthroscopy, Minimally Invasive Surgery and Sports Traumatology, Medical University of Lodz, Zeromskiego 113, 90-549 Lodz, Poland.ORCID 0000-0002-3486-3555
Zofia Gerlicz-KowalczukDepartment of Dermatology, Pediatric Dermatology and Dermatological Oncology, Medical University of Lodz, Kosciuszki 4, 90-647 Lodz, Poland.ORCID 0000-0002-8109-287X
Piotr JurowskiDepartment of Ophthalmology and Vision Rehabilitation, Medical University of Lodz, Zeromskiego 113, 90-549 Lodz, Poland.
Medical University of Lodz · PLPolish Mother’s Memorial Hospital Research Institute · PL

Funding

Uniwersytet Medyczny w Lodzi 503/5-009-01/503- 51-002Uniwersytet Medyczny w Lodzi 503/5-009-01/503-51-004
6 · The paper itself

Abstract

Systemic sclerosis (SSc) is an autoimmune connective tissue disorder associated with multiple organ involvement. The aim of the study was to present two SSc patients who were diagnosed with ischemic retinopathy in both eyes. As a background to our case study, we decided to investigate the imbalance of angiogenesis factors in 25 SSc patients in relation to 25 healthy controls. Assays of matrix metalloproteinases-2 and -9 (MMP-2, MMP-9), tissue inhibitor of metalloproteinases-1 (TIMP-1) and -2 (TIMP-2), vascular endothelial growth factor (VEGF), and soluble VEGF receptor-2 (sVEGFR-2) in blood serum and tears were performed. A significantly increased levels of MMP-9 in serum and tears, (

Indexed as

IschemiaRetinal DiseasesScleroderma, SystemicBiomarkersFemaleHumansMatrix Metalloproteinase 2Matrix Metalloproteinase 9Middle AgedTissue Inhibitor of Metalloproteinase-1Tissue Inhibitor of Metalloproteinase-2Vascular Endothelial Growth Factor ABiomarkersMatrix Metalloproteinase 2Matrix Metalloproteinase 9MMP2 protein, humanMMP9 protein, humanTIMP1 protein, humanTIMP2 protein, humanTissue Inhibitor of Metalloproteinase-1Tissue Inhibitor of Metalloproteinase-2Vascular Endothelial Growth Factor AVEGFA protein, humanangiogenesisischemic retinopathyMMP-2MMP-9sclerodermasVEGFR-2TIMP-1TIMP-2VEGF

Identifiers

PMID33218057
PMCPMC7698901
OpenAlexW3101593150

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.